The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
 
Matthew Ingham
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech; Mirati Therapeutics
 
Jacob B Allred
No Relationships to Disclose
 
Katherine Gano
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Allergan (I)
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi Sankyo; deciphera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - Tricon Pharmaceuticals
 
Sosipatros Alexandros Boikos
No Relationships to Disclose
 
Nam Bui
Consulting or Advisory Role - NewBay Pharma; Tempus
 
James Lin Chen
Consulting or Advisory Role - Immune Design; Novartis; Syapse
Speakers' Bureau - Foundation Medicine; Novartis
Research Funding - Eisai
Patents, Royalties, Other Intellectual Property - MatchTX
 
Julia Lee Close
No Relationships to Disclose
 
Mahesh Seetharam
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - Abbvie/Stemcentrx; Abbvie/Stemcentrx; Celsion; Clovis Oncology; Dova Pharmaceuticals; Iovance Biotherapeutics; Stryker; Tesaro; Unleash
Speakers' Bureau - AstraZeneca; Merck; Tesaro
Research Funding - Merck (Inst)
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech